We are live on
!
Find out more
CCM
Copernicus Capital Management Portfolio holdings
AUM
$8.26M
1-Year Est. Return
37.91%
This Fund
S&P 500
This Quarter
Est. Return
+3.88%
1 Year Est. Return
+37.91%
3 Year Est. Return
+125.98%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$112M
AUM Growth
+$73.4M
(+188%)
Cap. Flow
+$67.8M
Cap. Flow
% of AUM
60.32%
Top 10 Holdings %
Top 10 Hldgs %
83.24%
Holding
19
New
5
Increased
9
Reduced
1
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$11.3M |
| 2 |
Humana
HUM
|
+$10.4M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$9.26M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$7.36M |
| 5 |
Illumina
ILMN
|
+$7.14M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Heron Therapeutics
HRTX
|
+$3.32M |
| 2 |
UnitedHealth
UNH
|
+$2.97M |
| 3 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$1.74M |
| 4 |
NVRO
NEVRO CORP.
NVRO
|
+$313K |
| 5 |
Zoetis
ZTS
|
+$3.98K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Vertex Pharmaceuticals
VRTX
$120B
| $13M | 11.56% |
70,849
+52,986
| +297% | +$9.26M |
|
|
2
Merck
MRK
$322B
| $11.8M | 10.52% |
+147,768
| New | +$11.3M |
|
|
3
Bristol-Myers Squibb
BMY
$126B
| $11M | 9.8% |
242,937
+157,937
| +186% | +$7.36M |
|
|
4
Humana
HUM
$47.4B
| $10.9M | 9.67% |
+41,000
| New | +$10.4M |
|
5
Thermo Fisher Scientific
TMO
$213B
| $10.6M | 9.4% |
35,976
+16,986
| +89% | +$4.68M |
|
|
6
Illumina
ILMN
$29.8B
| $10.1M | 8.94% |
28,081
+22,612
| +413% | +$7.14M |
|
7
Gilead Sciences
GILD
$162B
| $9.99M | 8.89% |
147,916
+106,970
| +261% | +$7.04M |
|
8
Intuitive Surgical
ISRG
$119B
| $5.88M | 5.23% |
33,603
+28,797
| +599% | +$4.93M |
|
|
9
Zoetis
ZTS
$31.3B
| $5.72M | 5.09% |
50,375
-38
| -0.1% | -$3.98K |
|
10
CareDx
CDNA
$1.94B
| $4.67M | 4.16% |
129,855
+64,911
| +100% | +$2.08M |
|
11
Sarepta Therapeutics
SRPT
$1.68B
| $4.56M | 4.06% |
+30,000
| New | +$3.65M |
|
12
IQVIA
IQV
$34.6B
| $4.18M | 3.72% |
25,986
+5,986
| +30% | +$840K |
|
|
FOLD
13
DELISTED
Amicus Therapeutics
FOLD
| $4.06M | 3.61% |
+325,000
| New | +$4.12M |
|
14
Stryker
SYK
$122B
| $3.82M | 3.4% |
18,597
+3,989
| +27% | +$762K |
|
|
SIEN
15
DELISTED
Sientra, Inc.
SIEN
| $2.22M | 1.97% |
+36,000
| New | +$2.59M |
|
|
16
Heron Therapeutics
HRTX
$86.9M
| – | – |
-135,946
| Closed | -$3.32M |
|
|
17
UnitedHealth
UNH
$385B
| – | – |
-12,000
| Closed | -$2.97M |
|
|
NVRO
18
DELISTED
NEVRO CORP.
NVRO
| – | – |
-5,000
| Closed | -$313K |
|
|
HZNP
19
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| – | – |
-66,000
| Closed | -$1.74M |
|
Similar funds
AAM
IR
YEPV
LC
MA
IFC
PVMCV
ARTA
Copernicus Capital Management's Q2 2019 Portfolio in Review
As of Q2 2019, Copernicus Capital Management held 19 positions worth $112M, up 188% from $39M the previous quarter. Its ten largest holdings account for 83% of the portfolio.
Copernicus Capital Management deployed $67.8M of net new capital in Q2 2019, opening 5 new positions and adding to 9 existing holdings. Its largest new stake was Merck: 147,768 shares worth $11.8M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Zoetis, an estimated $3.98K trimmed.
- Copernicus Capital Management's largest Q2 2019 buy was Merck: 147,768 shares worth $11.8M.
- Copernicus Capital Management added most to Vertex Pharmaceuticals in Q2 2019, an estimated $9.26M increase.
- Copernicus Capital Management's biggest Q2 2019 reduction was Zoetis, cutting an estimated $3.98K.
- Copernicus Capital Management fully exited Heron Therapeutics in Q2 2019, selling an estimated $3.32M.
- Copernicus Capital Management's ten largest holdings make up 83% of its $112M portfolio in Q2 2019.
- Copernicus Capital Management opened 5 new positions and closed 4 in Q2 2019.
- Copernicus Capital Management's portfolio value rose 188% quarter-over-quarter to $112M.
Based on Copernicus Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.